We are seeking a Research Assistant to join our R&D team. The Research Assistant will work in a small team setting to execute and improve workflows related to our platform for drug discovery of gene regulators in a production environment. The role will primarily involve cellular biology, biochemistry, and peptide preparation for high-throughput proteomics. The ideal candidate will have strong organizational skills, impeccable attention to detail, and the desire to work in a fast-paced, growing biotechnology startup environment.
Responsibilities
Culture of human cell lines and cell treatment with candidate drug compounds.
Extraction and preparation of proteins for analysis by mass spectrometry proteomics.
Development and optimization of standard operating procedures for new experimental workflows.
Execution of experimental and data analysis support for internal and external projects.
Training and mentorship of new assistants as needed.
Qualifications
Required
BS in Biological Sciences or Chemistry.
4+ years of hands-on laboratory experience.
Experience with cell culture of human cell lines.
Experience working within small molecule cancer drug development teams
Strong work ethic, organizational skills, and attention to detail.
Preferred
Industry experience in a research laboratory or production setting.
Experience with biochemistry, protein purification, or mass spectrometry proteomics.
About Talus Bio
Therapeutic development is on the verge of a revolution. The tools of genome sequencing have helped us discover which proteins are best to target across countless diseases. The problem is that most of these top-tier targets have been written off as undruggable because they don't fit into the "standard" experimental models developed by the pharmaceutical industry. Fundamental breakthroughs in proteomics technology being developed at Talus will allow us to unlock many of these targets for the first time.
Talus Bio's vision is to build a tech-bio therapeutics engine that will unlock the genome regulatory network (the "regulome") for systematic drug development. The regulome is responsible for interpreting the human genome by switching genes on and off at the correct time in the correct cells, and their malfunction is common across many diseases. Currently, less than 20 regulome targets have been drugged, leaving over 400 targets left to be addressed in cancer alone.
Our platform measures a drug’s ability to disrupt a gene regulator within its natural, non-engineered cellular environment. Furthermore, a single experiment using the platform measures activity for hundreds of gene regulators simultaneously, providing information on in-cell drug activity and specificity in a single experiment. To accomplish this, we combine innovative cell processing with high-sensitivity quantitative proteomics and advanced downstream analytics.
The science on which the company was founded was developed at the Altius Institute for Biomedical Research and the University of Washington in Seattle. The initial work was published in Cell Reports in 2020- and further written up in FierceBiotech. Talus Bio's investors include leading venture funds (including NFX, Fifty Years, FundersClub, Pioneer Fund, Axial, Boom Capital, and others), as well as grant support from the National Science Foundation.
Talus Bio
